Paediatrics Search
Paediatrics Paediatrics
asthma%20(pediatric)
ASTHMA (PEDIATRIC)

Asthma is a chronic inflammatory disease of the airways in the lungs of children and adults.
The patient usually complains of shortness of breath, chest tightness and coughing with wheezing.

A diagnosis of asthma in young children is more likely if they have symptom patterns, presence of risk factors for development of asthma and therapeutic response to controller treatment.
Goals of treatment are effective symptom control with minimal or no exacerbations, minimal or no nocturnal and daytime symptoms, no limitations on activities, minimal or no need for reliever treatment, and minimal adverse effects of medication.

Principles of Therapy

Management Plans for Long-Term Asthma Control:

 Recommended Medications Based on Level of Control1
 Treatment Steps  Daily Controller Medications
Children ≤5 years1 Children ≥6 years1
Step 1
  • No daily medication required

Reliever

  • As needed beta2-agonist (inhaled, short-acting)
  • No daily medication required

Reliever

  • As needed beta2-agonist (inhaled, short-acting)2

Other controller options:

  • Consider corticosteroid (inhaled, low-dose)
Step 2

Preferred Controller 

  • Corticosteroid (inhaled, low-dose)

Reliever 

  • As needed beta2-agonist (inhaled, short-acting)

Other controller options:

  • Leukotriene modifier
  • Intermittent corticosteroid (inhaled)

Preferred Controller  

  • Corticosteroid (inhaled, low-dose)

Reliever

  • As needed beta2-agonist (inhaled, short-acting)2

Other controller options:

  • Leukotriene modifier
  • Theophylline (low-dose)3
Step 3 Preferred Controller
  • Corticosteroid (inhaled, double low-dose)

Reliever

  • As needed beta2-agonist (inhaled, short-acting)2

Other controller options:

  • Corticosteroid (inhaled, low-dose) plus leukotriene modifier

Preferred Controller 

  • Corticosteroid (inhaled, low-dose) plus beta2-agonist (inhaled, long-acting)3 

Reliever (any of the following): 

  • As needed beta2-agonist (inhaled, short-acting)2
  • Corticosteroid (inhaled, low-dose) plus Formoterol4

Other controller options (any one of the following):

  • Corticosteroid (inhaled, high- or medium5-dose)
  • Corticosteroid (inhaled, low-dose)

Plus any one of the following:

  • Leukotriene modifier
  • Theophylline (low-dose, extended-release)3
Step 4
  • Continue controller treatment
  • Specialist referral

Reliever

  • As needed beta2-agonist (short-acting)

Other controller options:

  • Plus any one of the following:
  • Leukotriene modifier
  • Increase corticosteroid (inhaled) frequency
  • Intermittent corticosteroid (inhaled)

Preferred Controller

  • Corticosteroid (inhaled, medium-/high-dose) plus beta2-agonist (inhaled, long-acting) 

Reliever (any one of the following)

  • As needed beta2-agonist (inhaled, short-acting)2
  • Corticosteroid (inhaled, low-dose) plus Formoterol4

Other controller options:

  • Tiotropium bromide5
  • Corticosteroid (inhaled, high-dose)

Plus any one of the following:

  • Leukotriene modifier
  • Theophylline (extended-release, long-acting)3
Step 5 N/A

Step 4 therapy
Plus any one of the following:

  • Tiotropium bromide3
  • Corticosteroid (oral, lowest dose)
  • Anti-IgE (Omalizumab), anti-IL-5 (Mepolizumab3), anti-IL5 receptor (SC Benralizumab3)

Notes:

  • Patients with symptoms not controlled with step 3 treatment should be referred to a specialist for further management.
  • Tiotropium by mist inhaler is only to be given to patients ≥12 years of age with a history of exacerbations.

1Modified from: Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention 2018. pp 43 & 111.
2Short-acting inhaled beta2-agonists should be used as required to relieve symptoms. Other options for reliever medications include anticholinergic (inhaled), beta2-agonist (oral, short-acting), or Theophylline (≥12 years old).
3Contraindicated in children <12 years of age.
4Preferred for patients previously given low-dose Budesonide/Formoterol or low-dose Beclomethasone/Formoterol combination as maintenance & reliever regimen.
5Medium-dose inhaled corticosteroids preferred in children 6-11 years old.
 
 
 
 
 
 
 
 
                                           
  • Goals of asthma management are achieved through a cycle of:
    • Assess (diagnosis, symptom control, risk factors, inhaler technique, adherence, parent preference)
    • Adjust treatment (medications, non-pharmacological strategies, treatment of modifiable risk factors)
    • Review regularly response including medication effectiveness & side effects

Pharmacotherapy

Stepwise Therapy Based on Control

Step 1 - Use of Reliever, as Needed

  • For children who have infrequent viral wheezing episodes & no or few interval symptoms
  • Intermittent inhaled corticosteroids may be an option for children with intermittent viral-induced wheezing

Step 2 - Initial single controller treatment plus as needed beta2-agonist (short-acting)

  • For patients who require controller medications everyday in order to maintain control of their asthma
  • For children whose symptoms are not adequately controlled asthma symptoms or ≥3 exacerbations/year
  • For children whose symptom pattern are inconsistent with asthma but with frequent wheezing episodes
  • May be used as initial therapy for treatment-naive patients with persistent symptoms
  • Low-dose daily inhaled corticosteroid is preferred for children ≤5 years old
    • As needed inhaled corticosteroids may be considered in pre-schoolers with increased frequency of wheezing secondary to viral infections
  • It should be given for at least 3 months to achieve good asthma control
  • Leukotriene modifiers may reduce symptoms in pediatric patients with persistent asthma

Step 3 - Double the daily low-dose inhaled corticosteroids

  • Before stepping up, re-confirm asthma diagnosis, check inhaler technique & compliance to medications & inquire about exposure to risk factors
  • For patients whom symptoms were not controlled by low-dose inhaled corticosteroids after 3 months of initial therapy or if exacerbations persisted
  • If symptoms are not controlled by step 3 medications, patient should be referred to a specialist for further diagnostic evaluation
  • Addition of oral leukotriene modifiers to low-dose corticosteroids may be considered

Step 4 - Controller treatment continued

  • Reassess inhaler technique, medication adherence, trigger factors & reinvestigate diagnosis
  • Consider expert referral if doubling the dose of inhaled corticosteroids fails or if symptom control remains poor &/or flare-ups persist
  • If symptom control is still not achieved, may consider increasing the dose of inhaled corticosteroid for several weeks until improvement is seen 
  • Addition of oral leukotriene modifiers, low-dose oral corticosteroids, or Theophylline in children >12 years old may be considered if symptoms are still not controlled

Step 5 - Use of Reliever, as needed & Additional Controller Options

  • For children ≥6 years of age
  • Tiotropium via mist inhaler may be considered for adolescent patients ≥12 years w/ a history of exacerbations despite combination therapy in Step 4
  • Addition of anti-IgE (Omalizumab) may be considered in pediatric patients ≥6 years of age diagnosed w/ moderate-severe asthma when control is not achieved despite combination treatments
  • Additional anti-IL-5 (Mepolizumab) or anti-IL receptor (Benralizumab) may be considered for patients ≥12 years of age w/ severe uncontrolled eosinophilic asthma despite adherence to step 4 regimen
  • Treatment may be reassessed based on the patient’s eosinophilia seen during sputum exam
    • May be applied if w/ previous history of high-dose inhaled corticosteroid or inhaled corticosteroid w/ long-acting beta2-agonist therapy

Reliever Medications

Preferred Therapy

  • Beta2-Agonists (Inhaled, Short-Acting)
    • Most effective bronchodilator
    • Agents of choice for relief of bronchoconstriction during acute episodes of asthma & are useful for pre-treatment prior to exercise with effects lasting for 0.5 to 2 hours
    • Used only when necessary; increased use indicates that management should be re-assessed

Alternative Therapy

  • Anticholinergic (Inhaled)
    • Eg Tiotropium bromide, Ipratropium bromide 
    • Considered alternative to short-acting inhaled beta2-agonists because they may have a slower onset of action &/or higher risk for side effects
    • Have an additive effect when nebulized together with a short-acting beta2-agonists for exacerbations of asthma
    • Considered in patients who experience adverse effects (eg tachycardia, arrhythmia, tremor) from short-acting beta2-agonists
    • Tiotropium may help improve lung function & decrease interval to next asthma exacerbation
    • Not for long term management of asthmatic children
  • Beta2-Agonists (Oral, Short-Acting)
    • Reserved for children in whom inhaled therapy is not well-tolerated
    • More side effects than inhalation route

Controller Medications

Preferred Therapy

  • Corticosteroids (Inhaled)
    • These are the most effective anti-inflammatory medications used for asthma & are the preferred controller medications for patients with persistent asthma of all levels of severity
    • Discontinuation is followed by deterioration of control within weeks to months in some patients
    • To minimize side effects, upon achievement of control, corticosteroids should be titrated carefully to lowest effective dose to maintain control
      • Ciclesonide, a prodrug that is activated only in the lungs, may be an alternative with decreased oropharyngeal side effect
    • Addition of long-acting inhaled beta2-agonist is preferred when medium-dose inhaled corticosteroid fails
      • Improves lung function & symptoms, reduces exacerbations, decreases need of short-acting beta2-agonists, achieves faster clinical control of asthma, & may also be used to prevent exercise-induced asthma
    • Combination inhalers are available which may increase compliance

Alternative or Add-On Therapy

  • Beta2-Agonists (Inhaled, Long-acting)
    • Has no effect on airway inflammation, hence not used as a monotherapy
    • Most efficacious when given together with inhaled corticosteroids
      • Rapid clinical control of asthma is achieved than when inhaled glucocorticosteroids are given alone
      • Studies have shown increased mortality risk when given alone; should not be used as a substitute for corticosteroids
      • Causes improved symptom scores, decreased nocturnal asthma symptoms, improved lung function, decreased use of short-acting beta2-agonists, & reduced number of exacerbations
  • Beta2-Agonist (Oral, Long-acting)
    • May be considered as an alternative add-on therapy & should always be given with inhaled corticosteroids
    • Only used on rare occasions when more bronchodilation is needed
    • Less effective than inhaled beta2-agonists & poses increased risk of side effects
  • Corticosteroids (Oral)
    • Long-term use (>2 weeks) may be required for severely uncontrolled asthma
    • Long-term use should be used at the lowest possible dose
  • Cromones (Inhaled)
    • Limited use in long-term treatment of asthma
    • May be used for patients with mild persistent asthma & exercise-induced bronchoconstriction
    • Weak anti-inflammatory effect, less effective than low-dose inhaled corticosteroids
  • Leukotriene Modifiers (Oral)
    • When used as add-on therapy, may reduce the required dose of inhaled corticosteroid for patients with moderate to severe symptoms
      • When used as monotherapy for control of asthma, leukotriene modifiers are less effective than low-dose inhaled corticosteroids 
  • Monoclonal Antibodies (eg Benralizumab, Mepolizumab, Omalizumab)
    • Reduces asthma symptoms & exacerbations, &  the need for rescue medications
    • Omalizumab is indicated for moderate to severe asthma w/ allergic component not controlled by inhaled corticosteroids
    • Benralizumab & Mepolizumab may be considered for patients ≥12 years old w/ severe eosinophilic asthma not controlled by inhaled corticosteroids
    • Use of Reslizumab in patients <18 years of age w/ asthma has not been established
  • Theophylline (Oral, Extended-Release)
    • Treatment option for patients >12 years of age
    • Bronchodilator, which at low dose, has anti-inflammatory effects

Allergen-Specific Immunotherapy

  • Therapeutic option after strict avoidance of triggers & medical intervention have failed
  • May be given as subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT)
    • Life-threatening anaphylactic reactions have been reported with SCIT use
    • SLIT has been associated with mild oral & gastrointestinal (GI) symptoms
  • May reduce symptoms, medication use, improve allergen-specific & non-specific airway hyperresponsiveness & can possibly prevent asthma development in children with allergic rhinoconjunctivitis
  • Benefits must be weighed against adverse effects & inconvenience of length of therapy
  • Efficacy of extracts or regimens based on clinical trials should be put into consideration before initiating therapy

Inhalation Devices

 INHALATION DEVICES 
 Age  Device
 0-3 years Preferred: Pressurized metered-dose inhaler plus dedicated spacer w/ face mask
Alternate: Nebulizer w/ face mask
 4-5 years Preferred: Pressurized metered-dose inhaler plus dedicated spacer w/ mouthpiece
Alternate: Pressurized metered-dose inhaler plus dedicated spacer w/ face mask or nebulizer w/ mouthpiece or face mask
Modified from: Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: Updated 2018. p114.

Dosage Guidelines

ANTICHOLINERGICS (INHALED)1
Drug Available Strength Dosage Remarks
Long-Acting Adverse Reactions
  • Resp effects [upper respiratory tract infection (URTI), bronchitis, sinusitis]; CV effects (chest pain, palpitation); CNS effects (headache, dizziness); GI effects (dry mouth, bad taste, dyspepsia, nausea); Hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm)
Special Instructions
  • Use w/ caution in patients w/ prostatic hyperplasia, patients predisposed to narrow-angle glaucoma, bladder neck obstruction, myasthenia gravis
  • Avoid contact of eyes w/ inhalation soln
  • Check patient's inhaler technique for optimum delivery of drug
  • Not used as 1st-line treatment
    • Should be added to beta2-agonist therapy
Tiotropium bromide 1.25 mcg/puff ≥12 yr: 2 puffs 24 hrly
Short-Acting
Ipratropium bromide 20 mcg/puff MDI 2 puffs 6 hrly
Max dose: 12 puffs/day
250 mcg/2 mL & 500 mcg/2 mL inhalation soln unit dose 1 unit dose (250-500 mcg) via nebulizer 6-8 hrly as required
0.025% inhalation soln <6 yr: 0.4-1 mL (100-250 mcg) via nebulizer 6-8 hrly as required
6-12 yr: 1 mL (250 mcg) via nebulizer 6-8 hrly as required
1Bronchodilator combinations are available. Please see the latest MIMS for specific formulations.


BETA2-AGONISTS (BRONCHODILATORS) (INHALED)1
Drug Available Strength Dosage* Remarks
Short-Acting
Fenoterol 100 & 200 mcg/puff MDI Approved in some countries for childn >6 yr: 1-2 puff 8 hrly as required Adverse Reactions
  • CV effects (tachycardia, palpitations, cardiac arrhythmias especially in susceptible patients); CNS effects (headache, hyperactivity); Resp effects (mouth & throat irritation, paradoxical bronchospasm); Other effect (fine skeletal muscle tremor)
  • Potentially severe hypokalemia may result esp in acute severe asthma
  • Orciprenaline is less selective for beta2-receptors & therefore, side effects may be more common
Special Instructions
  • Use w/ caution in patients w/ hyperthyroidism, DM, myocardial insufficiency or arrhythmias
  • Monitor K levels in acute severe asthma
  • Check patient's inhaler technique for optimum delivery of drug
1.25 mg/2 mL soln for inhalation 10-20 drops via nebulizer up to 6 hrly as required
6-14 yr: 10 drops 8 hrly
1-6 yr: 5-10 drops 8 hrly
<1 yr: 3-7 drops 8 hrly
Orciprenaline (Metaproterenol) 750 mcg/puff MDI 1-2 puffs 8 hrly as required
Max dose: 12 puffs/day
Procaterol 10 mcg/puff MDI Approved in some countries for childn: 1 puff 6-12 hrly as required
Salbutamol (Albuterol) 100 mcg/dose (autohaler/evohaler) Immediate relief/prior to exertion: 100 mcg as single dose
For chronic or preventive treatment: 100 mcg 6-8 hrly
May increase to 200 mcg 6-8 hrly if necessary
Max dose: 1.2 mg/day
100 & 200 mcg/dose easyhaler
100 mcg/dose MDI
100 & 200 mcg/dose DPI
200 mcg/dose accuhaler DPI
200 mcg/dose diskhaler DPI
200 mcg/cap DPI
1 mg/mL, 2.5 mg/2.5 mL, 5 mg/2.5 mL inhalation soln unit dose 2.5-5 mg via nebulizer 6-8 hrly as required
5 mg/mL (0.5% soln) inhalation soln 10-15 kg: 0.25 mL (1.25 mg)
>15 kg: 0.5 mL (2.5 mg)
>12 yr: 0.5-1 mL (2.5-5 mg)
Dilute required amount of soln w/ normal saline to final volume of 2-3 mL via nebulizer over 10 min as required
Terbutaline 250 mcg/puff MDI 1-2 puffs 6-8 hrly as required
Max dose: 8 puffs/day
500 mcg/dose DPI, turbuhaler DPI 3-12 yr: 1 dose inhaled 6 hrly as required
For severe exacerbations: 2 doses
Max dose: 8 doses/day
2.5 mg/2 mL, 5 mg/2 mL inhalation soln <20 kg: 2.5 mg via nebulizer up to 6 hrly as required
>20 kg: 5 mg via nebulizer up to 6 hrly as required
Long-Acting2
Formoterol 4.5 mcg/dose turbuhaler DPI Approved in some countries for childn ≥6 yr: 1-2 doses inhaled 12-24 hrly
Max dose: 4 doses/day		 Adverse Reactions
  • CV effects (tachycardia, palpitations, cardiac arrhythmias especially in susceptible patients); CNS effects (headache, hyperactivity); Resp effects (mouth & throat irritation, paradoxical bronchospasm); Other effect (fine skeletal muscle tremor)
  • Potentially severe hypokalemia may result especially in acute severe asthma
Special Instructions
  • Use w/ caution in patients w/ hyperthyroidism, DM, myocardial insufficiency or arrhythmias
  • Monitor K levels in acute severe asthma
  • Check patient's inhaler technique for optimum delivery of drug
9 mcg/dose turbuhaler DPI Approved in some countries for childn ≥6 yr: 1 dose inhaled 12-24 hrly
Max dose: 2 doses/day
12 mcg/cap DPI Approved in some countries for childn ≥5 yr: 1 cap inhaled 12 hrly
Salmeterol 25 mcg/puff MDI ≥4 yr: 2 puffs 12 hrly
50 mcg/dose accuhaler DPI, diskhaler DPI ≥4 yr: 1 dose inhaled 12 hrly
*Please note: Doses for acute exacerbations can be higher than the recommended maintenance doses listed here.
1Inhaled bronchodilator combinations are available. Please see the latest MIMS for specific formulations.
2Should be used as an adjunct to inhaled corticosteroids in the management of asthma. Please see the latest MIMS for specific formulations of different combination products.


BETA2-AGONISTS (BRONCHODILATORS) (ORAL)1
Drug Dosage Remarks
Short-Acting Adverse Reactions
  • CNS effects (headache, sleep disturbances, agitation, hyperactivity & restlessness); CV effects (palpitations, cardiac arrhythmias especially in susceptible patients); Other effect (fine skeletal muscle tremor)
  • Potentially severe hypokalemia may result especially in acute severe asthma
  • Orciprenaline is less selective for beta2 receptors & therefore side effects may be more common
Special Instructions
  • Use w/ caution in patients w/ hyperthyroidism, DM, myocardial insufficiency or arrhythmias
  • Monitor K levels in acute severe asthma
Clenbuterol 1.2 mcg/kg/day PO divided 12 hrly
Fenoterol Approved for use in some countries for childn:
<1 yr: 1.25 mg PO 8-12 hrly
1-6 yr: 1.25-2.5 mg PO 8 hrly
6-14 yr: 2.5 mg PO 8 hrly
Hexoprenaline Approved for use in some countries for childn:
3-6 mth: 0.125 mg PO 12-24 hrly
6-12 mth: 0.125 mg PO 8-24 hrly
1-3 yr: 0.125-0.25 mg PO 8-24 hrly
3-6 yr: 0.25 mg PO 8-24 hrly
6-10 yr: 0.5 mg PO 8-24 hrly
Orciprenaline (Metaproterenol) 3-10 yr: 10 mg PO 6 hrly
Procaterol <6 yr: 1.25 mcg/kg/dose PO 12 hrly
>6 yr: 25 mcg PO 12-24 hrly
Salbutamol2 (Albuterol) 2-6 yr: 1-2 mg PO 6-8 hrly
Max dose: 12 mg/day
6-12 yr: 2 mg PO 6-8 hrly
Max dose: 24 mg/day
>12 yr: 2-4 mg PO 6-8 hrly
Max dose: 32 mg/day
Terbutaline <12 yr: 0.05 mg/kg/dose PO 8 hrly
Max dose: 5 mg/day
≥12 yr: 2.5-5 mg PO 8 hrly
Max dose: 15 mg/day
Long-Acting
Bambuterol Approved for use in some countries for childn 2-12 yr: 5-10 mg PO 24 hrly
Max dose for childn 2-5 yr: 10 mg/day (Doses >10 mg/day PO is not recommended in Asian childn 2-12 yr)
Formoterol 4 mcg/kg/day PO divided 8-12 hrly
Salbutamol (Albuterol) Extended-release:
 <12 yr: 0.3-0.6 mg/kg/day divided 12 hrly
>12 yr: 4 mg PO 12 hrly
1Oral bronchodilator combinations are available. Please see the latest MIMS for specific formulations.
2Combination w/ other cough preparation is available. Please see the latest MIMS for specific formulations.


BRONCHODILATORS (PARENTERAL)
Drug Dosage Remarks
Beta2-Agonists
Hexoprenaline 5-10 mcg slow IV inj x 3-4 doses in 24 hr Adverse Reactions
  • Fine skeletal muscle tremor, palpitations, cardiac arrhythmias esp in susceptible patients, headache, sleep disturbances, agitation, hyperactivity & restlessness
  • Potentially severe hypokalemia may result esp in acute severe asthma
  • Epinephrine: Dyspnea, hyperglycemia, restlessness, palpitations, tachycardia, tremors, sweating, hypersalivation, weakness, dizziness, headache, coldness of extremities, hypertension, flushing, hypotension
Special Instructions
  • Use w/ caution in patients w/ hyperthyroidism, DM, myocardial insufficiency or arrhythmias
  • Monitor K levels in acute severe asthma
Salbutamol 250 mcg slow IV inj, may repeat as required
500 mcg IM/SC, may repeat 4 hrly as required
IV infusion: 3-20 mcg/min IV infusion
Terbutaline 2-15 yr: 10 mcg/kg/dose SC/slow IV up to 6 hrly as required
Max dose: 300 mcg/dose
IV infusion: 25 mcg/kg/day IV as a continuous infusion
Nonspecific Sympathomimetic
Epinephrine (Adrenaline) 10 mcg/kg up to 300-500 mcg SC/IM every 20 min x 3 doses


CORTICOSTEROIDS (INHALED)1
Drug Available Strength Dosage Remarks
Beclomethasone dipropionate 50, 100, 250 mcg/puff MDI

Childn <5 yr:
HFA-based
Low dose: 100 mcg3
Medium dose: >200-400 mcg
High dose: >400 mcg

Childn 6-11 yr:
CFC-based
Low dose: 100-200 mcg
Medium dose: >200-400 mcg
High dose: >400 mcg

HFA-based
Low dose: 50-100 mcg
Medium dose: >100-200 mcg
High dose: >200 mcg

Childn >12 yr & Adults:
CFC-based
Low dose: 200-500 mcg
Medium dose: >500-1000 mcg
High dose: >1000 mcg

HFA-based
Low dose: 100-200 mcg
Medium dose: >200-400 mcg
High dose: >400 mcg

 Adverse Reactions
  • Local effects (oropharyngeal candidiasis, cough from upper airway irritation, dysphonia); paradoxical bronchospasm (rare)
  • Long-term use of high-dose steroids may result in cataracts, glaucoma, skin thinning, easy bruising, adrenal suppression, increased bone loss & osteoporotic fractures
  • Risk of systemic effects will depend on dose, potency of the corticosteroid, absorption from the gut, delivery system, the use of spacers & the drug’s pharmacokinetics
Special Instructions
  • Local effects may be minimized by using a spacer, gargling & spitting out w/ water, or gargling w/ 1:50 dilution of Amphotericin B
100, 200 mcg/cap DPI; 100, 200 mcg/dose diskhaler DPI;
200 mcg/dose easyhaler DPI
Budesonide 100, 200 mcg/puff MDI

Childn <5 yr:
Low dose: 200 mcg
Medium dose: >200-400 mcg
High dose: >400 mcg

Nebules
Low dose: 500 mcg4
Medium dose: >500-1000 mcg
High dose: >1000 mcg

Childn 6-11 yr:
Low dose: 100-200 mcg
Medium dose: >200-400 mcg
High dose: >400 mcg

Nebules
Low dose: 250-500 mcg
Medium dose: >500-1000 mcg
High dose: >1000 mcg

Childn >12 yr & Adults:
Low dose: 200-400 mcg
Medium dose: >400-800 mcg
High dose: >800 mcg
100, 200, 400 mcg/dose turbuhaler DPI; 200 mcg/dose swinghaler;
200 mcg/dose easyhaler;
100, 200, 400 mcg/cap DPI
250 mcg/2 mL, 500 mcg/2 mL, 500 mcg/mL, 1 mg/2 mL soln for inhalation unit dose
Ciclesonide 80, 160 mcg/actuation MDI

Childn <5 yr:
Low dose: 160 mcg
Medium dose: >160-320 mcg
High dose: >320 mcg
Once-daily dosing in patients w/ mild severity of asthma

Childn 6-11 yr:
Low dose: 80 mcg
Medium dose: >80-160 mcg
High dose: >160 mcg

Childn >12 yr & Adults:
Low dose: 80-160 mcg
Medium dose: >160-320 mcg
High dose: >320 mcg

Flunisolide 500 mcg/puff MDI

Childn <5 yr:
Low dose: 500-750 mcg
Medium dose: >750-1250 mcg
High dose: >1250 mcg

Fluticasone furoate 50, 100, 250 mcg/dose accuhaler DPI;
50, 250 mcg dose diskhaler DPI;
50, 125, 250 mcg/dose evohaler 		Childn >12 yr & Adults:
Low dose: 100 mcg
High dose: 200 mcg
Fluticasone propionate 50, 125, 250 mcg/puff MDI

Childn <5 yr:
Low dose: 100 mcg5 
Medium dose: >200-500 mcg
High dose: >500 mcg

Childn 6-11 yr:
Low dose: 100-200 mcg
Medium dose: >200-500 mcg
High dose: >400-500 mcg

Childn >12 yr & Adults:
Low dose: 100-250 mcg
Medium dose: >250-500 mcg
High dose: >500 mcg

50, 100, 250 mcg/dose accuhaler DPI;
50, 250 mcg dose diskhaler DPI;
50, 125, 250 mcg/dose evohaler
0.5 mg/2 mL, 2 mg/2 mL soln for inhalation unit dose
Mometasone furoate2 50, 100, 200 mcg/dose for inhalation unit dose

Childn 6-11 yr:
Low dose: 100 mcg5 
Medium dose: ≥220-<440 mcg
High dose: ≥440 mcg

Childn >12 yr & Adults:
Low dose: 110-220 mcg
Medium dose: >220-440 mcg
High dose: >440 mcg

Triamcinolone acetonide2 75, 200 mcg/dose for inhalation unit dose

Childn 6-11 yr:
Low dose: 400-800 mcg
Medium dose: >800-1200 mcg
High dose: >1200 mcg

Childn >12 yr & Adults:
Low dose: 400-1000 mcg
Medium dose: >1000-2000 mcg
High dose: >2000 mcg

1Corticosteroids combined w/ bronchodilators are available. Please see the latest MIMS for specific formulations.
2Approved for once-daily dosing in patients w/ mild severity of asthma.
3Ages ≥5 years
4Ages ≥1 year
5Ages ≥4 years
Modified from: Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: Updated 2018. p45, 112.


CORTICOSTEROIDS (SYSTEMIC)
Drug Dosage Remarks
Dexamethasone Childn: 0.08-0.3 mg/kg BW/day IV/IM, divided 6-12 hrly
 Adverse Reactions
  • CNS effects (excessive mental stimulation, insomnia & psychic disturbances); CV effect (tachycardia); Other effects (increased appetite, wt gain, muscle weakness)
Hydrocortisone Asthma exacerbations in emergency dept:
2-4 mg/kg/dose slow IV/IV infusion 6 hrly x 24 hr
Adjust dose according to response & reduce over 4-5 days to oral dose when tolerated		 Adverse Reactions
  • GI effect (gastritis). If administered long-term: adrenocortical insufficiency, osteoporosis, muscle wasting, pain or weakness, increased susceptibility to infection, impaired wound healing, electrolyte imbalances, wt gain, DM, skin thinning leading to striae & easy bruising, cataracts, glaucoma
Special Instructions
  • Should be taken w/ food
  • Patients on long-term corticosteroids should receive preventive treatment for osteoporosis
Methylprednisolone, Prednisolone, Prednisone 1-2 mg/kg/day PO divided 6-8 hrly x 3-10 days
Max dose: 60 mg/day


COUGH & COLD PREPARATIONS
Drug Dosage Remarks
Ambroxol ≤6 mth: 1.25 mL PO 12 hrly
7 mth-2 yr: 2.5 mL PO 12 hrly
2-6 yr: 2.5 mL PO 8 hrly
7-12 yr: 5 mL PO 8-12 hrly 		Adverse Reactions
  • GI effect (N/V, diarrhea); Other effects (headache, polyuria, fatigue)
Special Instruction
  • Should not be taken in an empty stomach
  • Use w/ caution in patients w/ gastric ulcer
Bromhexine <5 yr: 2 mg PO 8 hrly
5-10 yr: 4 mg PO 8 hrly
>10 yr: 8 mg PO 8 hrly		 Adverse Reactions
  • GI effect (GI irritation); Metabolic effect (transient increase of serum transaminases)
Special Instruction
  • Use w/ caution in patients w/ gastric ulcer
Dried ivy leaf extract Syr
6-10 yr: 5 mL PO 8 hrly
1-5 yr: 2.5 mL PO 8 hrly
Effervescent Tab
6-12 yr: 32.5 mg PO 12 hrly 		Adverse Reactions
  • Rarely, laxative effect due to sorbitol content
Special Instructions
  • Use w/ caution in patients w/ fructose/sorbitol intolerance
Guaifenesin Infant: 25 mg PO 6 hrly
2-6 yr: 10-50 mg PO 4-6 hrly
≥7 yr: 20-100 mg PO 4-6 hrly
Max Dose ≥6 yr: 600 mg/day		 Adverse Reactions
  • GI effects (GI discomfort; N/V); CNS effects (drowsiness; headache)
Special Instruction
  • Use w/ caution in childn <2 years old & in patients w/ persistent or chronic cough
Lagundi (Vitex negundo) 15 mg/kg/dose or
2.5 mL/kg/dose 8 hrly		 Adverse Reactions
  • GI effects (N/V, diarrhea); Dermatologic effect (rash)
Special Instruction
  • Use w/ caution in patients w/ hypersensitivity to Lagundi


CROMONE (INHALED)
Drug Available Strength Dosage Remarks
Cromoglicic acid (Cromolyn Na, Na cromoglicate, Na cromoglycate) 5 mg/puff MDI 2 puffs 6 hrly
May increase to 2 puffs 6-8x/day in more severe cases & reduce to 1 puff 6 hrly once asthma has been stabilized		 Adverse Reactions
  • Resp effects (transient bronchospasm, cough & irritation of throat, rarely, severe bronchospasm, angioedema, laryngea l edema & anaphylaxis); Other effects (unpleasant taste, nausea, headache)
Special Instructions
  • Should not be used for acute asthma attacks


LEUKOTRIENE MODIFIERS (ORAL)
Drug Dosage Remarks
5-Lipoxygenase
Zileuton ≥12 yr: 600 mg PO 6 hrly
Extended-release: 1.2 g PO 12 hrly		 Adverse Reactions
  • CNS effect (headache); GI effects (GI upset, raised liver enzymes); Other effects (rashes, leukopenia has occurred in a few patients)
Special Instructions
  • Avoid in patients w/ hepatic impairment/disease
  • Monitor liver enzymes before & periodically during therapy
  • Should not be used for acute asthma attacks
Leukotriene Receptor Antagonists
Montelukast 6 mth-5 yr: 4 mg PO 24 hrly before bedtime
6-14 yr: 5 mg PO 24 hrly before bedtime
≥15 yr: 10 mg PO 24 hrly before bedtime		 Adverse Reactions
  • Generally well-tolerated: headache, GI upset
  • Less commonly: generalized pain, arthralgia, myalgia, fever, dizziness; hypersensitivity reactions
  • Zafirlukast: raised liver enzymes, rarely symptomatic hepatitis, hyperbilirubinemia
  • Very rarely: agranulocytosis, bleeding, bruising & edema, systemic eosinophilia consistent w/ Churg-Strauss disease
Special Instructions
  • Should not be used for acute asthma attacks
  • Zafirlukast: Avoid in patients w/ hepatic impairment or cirrhosis
Pranlukast 3.5 mg/kg PO 12 hrly
Max dose: 10 mg/kg/day
Zafirlukast 5-11 yr: 10 mg PO 12 hrly
≥12 yr: 20 mg PO 12 hrly


MAST CELL STABILIZER/ANTIHISTAMINE (ORAL)
Drug Dosage Remarks
Ketotifen 6 mth-3 yr: 0.5 mg PO 12 hrly
>3 yr: 1 mg PO 12 hrly
Extended-release:
>3 yr: 2 mg PO at bedtime		 Adverse Reactions
  • CNS effects (drowsiness, dizziness, CNS stimulation); GI effects (dry mouth, increased appetite, wt gain)
Special Instructions
  • Should not be used for acute asthma attacks


METHYLXANTHINES (ORAL)
Drug Dosage Remarks
Acefylline 500 mg-2 g/day PO in divided doses Adverse Reactions
  • GI effects (irritation, N/V, abdominal pain, diarrhea, gastroesophageal reflux); CNS effects (CNS stimulation, headache, anxiety, restlessness, dizziness, tremor); Other effect (palpitations)
  • Serum concentration >15-20 mcg/mL (85-110 micromol/L) are associated w/ increased risk of adverse effects including lethal adverse reactions
Special Instructions
  • Use w/ caution in patients w/ peptic ulcer, hyperthyroidism, hypertension, cardiac arrhythmias or other CV disease, epilepsy, heart failure, hepatic dysfunction, acute febrile illness, in neonates
  • Many drug interactions occur w/ Theophylline including smoking
    • Increases Theophylline clearance
  • Serum concentration monitoring is necessary to ensure that concentration are within therapeutic range
    • Serum concentration needs to be measured if a patient is changed from one extended-release product to another
  • Optimal therapeutic concentration: 5-15 mcg/mL (28-85 micromol/L)
Aminophylline Dosage should be individualized
Choline Theophyllinate 100 mg PO 6-8 hrly
Diprophylline (Dyphylline) 15 mg/kg/dose PO 6 hrly
Doxofylline <12 yr: 6-9 mg/kg/dose PO 12 hrly
>12 yr: 200 mg PO 8-24 hrly
Heptaminol acefyllinate >15 yr: 500 mg-1 g PO 8 hrly
Theophylline1 Acute bronchospasm:
Loading dose in patients not taking methylxanthine: 5 mg/kg PO
Maintenance dose:
6 mth-<1 yr: 12-18 mg/kg/day
1-<9 yr: 20-24 mg/kg/day
9-<12 yr (including adolescent smokers): 16 mg/kg/day
12-16 yr (nonsmokers): 13 mg/kg/day
1Different formulations for Theophylline are available. Please see the latest MIMS for specific formulations.


METHYLXANTHINES (PARENTERAL)
Drug Dosage Remarks
Acefylline 1.5-2 g/day IM
0.5-1 g/day IV		 Adverse Reactions
  • GI effects (irritation, N/V, abdominal pain, diarrhea, gastroesophageal reflux); CNS effects (CNS stimulation, headache, anxiety, restlessness, dizziness, tremor); Other effect (palpitations)
  • Serum concentration >15-20 mcg/mL (85-110 µ/L) are associated w/ increased risk of adverse effects including lethal adverse reactions
Special Instructions
  • Administer IV inj very slowly to prevent dangerous CNS & CV side effects
  • Use w/ caution in patients w/ peptic ulcer, porphyria, hyperthyroidism, hypertension, cardiac arrhythmias or other CV disease, epilepsy, heart failure, hepatic dysfunction, acute febrile illness, in neonates
  • Serum concentration monitoring is necessary to ensure concentration are within therapeutic range
  • Optimal therapeutic concentration: 5-15 mcg/mL (28-85 µ/L)
Aminophylline Loading dose: 5 mg/kg IV infusion over 20-30 min
Maintenance dose:
6 mth-9 yr: 1 mg/kg/hr
10-16 yr: 0.8 mg/kg/hr
Proxyphylline 400-800 mg IM or slow IV 8 hrly


MONOCLONAL ANTIBODIES
Drug Dosage Remarks
Anti-Immunoglobulin E (Anti-IgE) Antibody
Omalizumab ≥12 yr: 150-375 mg SC every 2 or 4 wk
Max dose: 375 mg every 2 wk
Dose depends on pretreatment IgE level & body wt		 Adverse Reactions
  • CNS effect (headache); Resp effects (resp infections, sinusitis, pharyngitis); Other effects (local site reaction, viral infection, anaphylaxis, malignancies)

Special Instructions

  • Max of 150 mg should be delivered per inj site
  • Should not be used for the treatment of acute bronchospasm or status asthmaticus
  • Contraindicated in patients w/ severe hypersensitivity to the drug & in children <12 years old
  • Corticosteroids should be tapered gradually
  • Use w/ caution in patients at risk of parasitic infections
Interleukin Inhibitor
Mepolizumab ≥12 yr, ≥45 kg: 100 mg SC 24 hrly every 4 wk Adverse Reactions
  • Dermatologic effects (pruritus, eczema, inj site reaction including erythema, swelling, itching, burning); Musculoskeletal effects (muscle spasm, back pain); Resp effects (nasal congestion, dyspnea, allergic rhinitis, bronchospasm); Misc effects (UTI, headache, toothache, infection)
Special Instructions
  • Not for acute asthma treatment
  • Use w/ caution in patients w/ uncontrolled worsening asthma, helminth infection, children <12 years old, <45 kg, abrupt steroid withdrawal
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Guselkumab tops secukinumab for moderate-to-severe plaque psoriasis
Roshini Claire Anthony, 3 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Aspirin, other NSAIDs at standard doses may lower endometrial cancer risk in obese women
Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
JAK3 inhibitors zoom in as potential cure for spot baldness
Elvira Manzano, 4 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
TKI treatment discontinuation in chronic myeloid leukaemia feasible in clinical practice
2 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.